Allurion Announces Strong Start to U.S. Launch with Exceptional Early Outcomes and Growth Momentum

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (OTCQB: ALUR), a pioneer in metabolically healthy weight loss, today announced successful early traction in the launch of the Allurion Program in the United States, marked by strong clinical outcomes, rapid account growth, high re-order rates, and performance exceeding internal expectations. First shipments of the Allurion Smart Capsule were completed in April, with the first U.S. patients treated that same month. Early clinical outcom.

Business Wire • Jun 2, 2026

Allurion Treats First Commercial Patients in the United States, Marking Major Milestone

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (OTCID: ALUR), a pioneer in metabolically healthy weight loss, today announced the successful commercial treatment of its first patients in the United States—an inflection point that formally launches the company into the world's largest and most dynamic obesity market. Allurion is seeing growing demand from patients who have discontinued GLP-1 therapy due to side effects, long-term commitment concerns, or weight regain following disco.

Business Wire • Apr 20, 2026

Allurion Advances Plan to Regain Listing Compliance

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (the “Company”) (OTCID: ALUR), a pioneer in metabolically healthy weight loss, announced today that it has appealed the decision by the New York Stock Exchange (the “NYSE”) to initiate delisting proceedings against Allurion's securities pursuant to Section 802.01B of the NYSE's Listed Company Manual, which requires listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least.

Business Wire • Mar 12, 2026

Allurion Begins Training and On‑Boarding of U.S. Accounts, Marking Major Milestone in Expansion Strategy

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (OTCID: ALUR), a pioneer in metabolically healthy weight loss, today announced that it has officially begun training and on‑boarding partner accounts across the United States, including large academic medical centers and private practices. The company has begun manufacturing FDA-approved product and expects to begin shipping in April. This milestone represents a pivotal step in the company's commercial expansion into the world's larges.

Business Wire • Mar 11, 2026

NYSE to Commence Delisting Proceedings Against Allurion Technologies, Inc. (ALUR)

NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the two securities enumerated below (“Securities”) of Allurion Technologies, Inc. (the “Company”) from the NYSE. NYSE Regulation reached its decision to commence proceedings to delist the Company's Securities pursuant to Section 802.01B of the NYSE's Listed Company Manual because the Company had fallen below the NYSE's.

Business Wire • Mar 6, 2026

Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, has received notice from the New York Stock Exchange (NYSE) that it intends to initiate delisting proceedings against Allurion after the Company was unable to demonstrate that it had regained compliance with Section 802.01B of the Listed Company Manual requiring listed companies to maintain either (i) at least $50 million in stockholders' equity or (ii) at le.

Business Wire • Mar 2, 2026

Are Medical Stocks Lagging Allurion Technologies, Inc. (ALUR) This Year?

Here is how Allurion Technologies, Inc. (ALUR) and McKesson (MCK) have performed compared to their sector so far this year.

Zacks Investment Research • Feb 27, 2026

Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (the “Company” or “Allurion”), a pioneer in metabolically healthy weight loss, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,659,565 shares of common stock, issued by the Company on January 27, 2025 (the “January 2025 Warrants”), February 20, 2025 (the “February 2025 Warrants”) and November 12, 2025 (the “November 2025 Wa.

Business Wire • Feb 24, 2026

Allurion Receives U.S. FDA Approval

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval (PMA) application for the Allurion Gastric Balloon System, featuring the Allurion Smart Capsule. “Today's approval is a watershed moment for Allurion and for obesity care in the United States,” said Dr. Shantanu Gaur, Founder and Chief Executive Officer. “Our goal is to deliv.

Business Wire • Feb 23, 2026

Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a partnership with Bionut, a leader in obesity care in Argentina, and Farmastar, a local pharmacy partner with access to the official supplier of Mounjaro (tirzepatide) in Argentina, to provide patients with access to discounted Mounjaro to be used in combination with the Allurion Smart Capsule. “The obesity epidemic is growing, and patients are in need of mo.

Business Wire • Feb 3, 2026